交银国际：上调百济神州(06160)目标价至231港元 维持“买入”评级

Core Viewpoint - The report from CMB International indicates a strong performance by BeiGene (06160) in Q3, leading to an upward revision of the group's net profit forecast by 3% to 52% [1] Financial Performance - The company has raised its revenue guidance for 2025 to between $5.1 billion and $5.3 billion [1] - GAAP operating expenses guidance has been lowered to between $4.1 billion and $4.3 billion [1] Investment Outlook - The target price for BeiGene has been increased to HKD 231, suggesting an upside potential of 18.2% [1] - The rating has been maintained at "Buy" [1]